Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects [PDF]
Frontiers in Microbiology, 2018 Carbapenem-resistant Enterobacteriaceae (CRE), a major resistance concern emerging during the last decade because of significantly compromising the efficacy of carbapenem agents, has currently become an important focus of infection control.
Shio-Shin Jean +8 more
doaj +8 more sources
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections [PDF]
Emerging Infectious Diseases, 2014 We evaluated the number of deaths attributable to carbapenem-resistant Enterobacteriaceae by using studies from around the world published before April 9, 2012.
Matthew E. Falagas +3 more
doaj +6 more sources
Carbapenem and colistin resistance in children with Enterobacteriaceae infections [PDF]
The Turkish Journal of Pediatrics, 2020 Background. Carbapenem-resistant Enterobacteriaceae (CRE) are an emerging global public health threat. As a reserve agent, colistin has been the drug of choice for the treatment of infections caused by CRE.
Zeliha Haytoğlu +5 more
doaj +5 more sources
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. [PDF]
J Pediatric Infect Dis Soc, 2020 Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes. Optimal treatment strategies for CRE infections continue to evolve.
Chiotos K, Hayes M, Gerber JS, Tamma PD.
europepmc +6 more sources
Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. [PDF]
Infection, 2023 Objective Carbapenem-resistant Enterobacteriaceae (CRE) pose a significant threat to human health and have emerged as a major public health concern. We aimed to compare the efficacy and the safety of ceftazidime–avibactam (CAZ–AVI) and polymyxin in the ...
Chen J, Hu Q, Zhou P, Deng S.
europepmc +2 more sources
Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review. [PDF]
Infect Drug Resist, 2022 Objective Carbapenem-resistant Enterobacteriaceae (CRE) has become a significant public health problem in the last decade. We aimed to explore the risk factors of mortality in patients with CRE infections and to focus on the current evidence on ...
Hu Q, Chen J, Sun S, Deng S.
europepmc +2 more sources
Paediatric Enterobacteriaceae infections in hospitalised children in Durban, KwaZulu-Natal
Southern African Journal of Infectious Diseases, 2021 Background: Community-acquired Gram-negative Enterobacteriaceae infections in malnourished and HIV-infected hospitalised children are not well documented and are of concern because of increasing antibiotic resistance and limited available treatment ...
Harshna Krishinchand +3 more
doaj +2 more sources
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. [PDF]
Clin Infect Dis, 2020 Twenty patients with carbapenem-resistant Enterobacteriaceae (CRE) infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively.
Shields RK +10 more
europepmc +2 more sources
Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. [PDF]
Infect Dis Ther, 2020 Background The aim of this study was to evaluate the predictive performance of the INCREMENT-CPE (ICS), Pitt bacteremia score (PBS) and qPitt for mortality among patients treated with ceftazidime–avibactam for carbapenem-resistant Enterobacteriaceae (CRE)
Jorgensen SCJ +12 more
europepmc +2 more sources
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. [PDF]
Antimicrob Agents Chemother, 2020 The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown.
Ackley R +6 more
europepmc +2 more sources